HomeCompareCZNB vs ABBV

CZNB vs ABBV: Dividend Comparison 2026

CZNB yields 2000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CZNB wins by $1.6088281902868016e+32M in total portfolio value
10 years
CZNB
CZNB
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-26.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6088281902868016e+32M
Annual income
$160,520,438,920,596,040,000,000,000,000,000,000,000.00
Full CZNB calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CZNB vs ABBV

📍 CZNB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCZNBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CZNB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CZNB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CZNB
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$136,442,373,082,506,640,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CZNB beats the other by $136,442,373,082,506,640,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CZNB + ABBV for your $10,000?

CZNB: 50%ABBV: 50%
100% ABBV50/50100% CZNB
Portfolio after 10yr
$8.044140951434008e+31M
Annual income
$80,260,219,460,298,020,000,000,000,000,000,000,000.00/yr
Blended yield
99.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CZNB
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CZNB buys
0
ABBV buys
0
No recent congressional trades found for CZNB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCZNBABBV
Forward yield2000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-26.9%40.6%
Portfolio after 10y$1.6088281902868016e+32M$102.3K
Annual income after 10y$160,520,438,920,596,040,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$1.6085907776646741e+32M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CZNB vs ABBV ($10,000, DRIP)

YearCZNB PortfolioCZNB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$146,210,700$146,200,000.00$11,550$430.00+$146.20MCZNB
2$1,460,517,115,780$1,460,360,670,330.84$13,472$627.96+$1460517.10MCZNB
3$9,967,570,536,270,028$9,966,007,782,956,144.00$15,906$926.08+$9967570536.25MCZNB
4$46,476,900,685,019,410,000$46,466,235,384,545,600,000.00$19,071$1,382.55+$46476900685019.39MCZNB
5$148,069,229,004,952,620,000,000$148,019,498,721,219,650,000,000.00$23,302$2,095.81+$148069229004952608.00MCZNB
6$322,324,789,449,701,950,000,000,000$322,166,355,374,666,700,000,000,000.00$29,150$3,237.93+$322324789449701982208.00MCZNB
7$479,463,095,715,790,140,000,000,000,000$479,118,208,191,078,900,000,000,000,000.00$37,536$5,121.41+$4.794630957157902e+23MCZNB
8$487,410,758,732,831,160,000,000,000,000,000$486,897,733,220,415,300,000,000,000,000,000.00$50,079$8,338.38+$4.8741075873283114e+26MCZNB
9$338,672,998,209,461,400,000,000,000,000,000,000$338,151,468,697,617,300,000,000,000,000,000,000.00$69,753$14,065.80+$3.3867299820946145e+29MCZNB
10$160,882,819,028,680,150,000,000,000,000,000,000,000$160,520,438,920,596,040,000,000,000,000,000,000,000.00$102,337$24,771.77+$1.6088281902868016e+32MCZNB

CZNB vs ABBV: Complete Analysis 2026

CZNBStock

Citizens Bancorp was founded in 1995 and is based in Nevada City, California.

Full CZNB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CZNB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CZNB vs SCHDCZNB vs JEPICZNB vs OCZNB vs KOCZNB vs MAINCZNB vs JNJCZNB vs MRKCZNB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.